Clopidogrel (Plavix)

DRUG3 trials

Sponsors

Sanofi, Gyeongsang National University Hospital, Ronald Hoffman

Conditions

Myocardial InfarctionPeripheral Arterial DiseasePolycythemia Vera

Phase 2

Clopidogrel and Aspirin for the Treatment of Polycythemia Vera

WithdrawnNCT00940784

Ronald HoffmanPolycythemia Vera

Start: 2009-06-30End: 2011-01-31Updated: 2014-11-26

Phase 4

Effect of Plavix on NO (Nitrogen Monoxide) Production of the Endothelial Function

CompletedNCT00648453

SanofiPeripheral Arterial Disease

Start: 2002-12-31End: 2004-04-30Updated: 2008-04-03

Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction (AMI) Patients According to CYP2C19 Polymorphism

CompletedNCT00915733

Gyeongsang National University HospitalMyocardial Infarction

Start: 2009-05-31End: 2009-11-30Updated: 2009-11-10

Related Papers

Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study.

2012-04-016 citations

Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype.

2011-04-0142 citations

Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study.

2010-07-0155 citations